ARROWSTAR RESOURCES
Adastra Holdings Ltd. extracts and processes cannabis for recreational and medical markets in Canada. The company offers vape pens, wax, resin, infused pre-rolls, diamonds, and shatters under the Endgame brand name. It also provides consulting, white label manufacturing, and tolling services; and licenses its intellectual property for the sale of consumer-packaged goods. The company was formerly … Read more
ARROWSTAR RESOURCES (D2E) - Net Assets
Latest net assets as of March 2024: €13.37 Million EUR
Based on the latest financial reports, ARROWSTAR RESOURCES (D2E) has net assets worth €13.37 Million EUR as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€30.79 Million) and total liabilities (€17.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.37 Million |
| % of Total Assets | 43.44% |
| Annual Growth Rate | 13.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 66.37 |
ARROWSTAR RESOURCES - Net Assets Trend (2020–2023)
This chart illustrates how ARROWSTAR RESOURCES's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ARROWSTAR RESOURCES (2020–2023)
The table below shows the annual net assets of ARROWSTAR RESOURCES from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €14.69 Million | -19.44% |
| 2022-12-31 | €18.23 Million | -18.52% |
| 2021-12-31 | €22.37 Million | +121.82% |
| 2020-12-31 | €10.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ARROWSTAR RESOURCES's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1057622000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €36.44 Million | 248.14% |
| Total Equity | €14.69 Million | 100.00% |
ARROWSTAR RESOURCES Competitors by Market Cap
The table below lists competitors of ARROWSTAR RESOURCES ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jyske Invest Virksomhedsobligationer
CO:JYIVIRK
|
$132.19K |
|
Cirsa Enterprises SAU
MC:CIRSA
|
$132.23K |
|
AgomAb Therapeutics NV American Depositary Shares
NASDAQ:AGMB
|
$132.29K |
|
Tadir-Gan (Precision Products) 1993 Ltd
TA:TDGN
|
$132.47K |
|
HERBALIFE
MU:HOO
|
$132.12K |
|
BITB39
SA:BITB39
|
$132.07K |
|
Nordea Inv. Verdens Obl.marked KL 1
CO:NDIVOMKL1
|
$132.06K |
|
Public Policy Holding Company, Inc. Common Stock
NASDAQ:PPHC
|
$132.05K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ARROWSTAR RESOURCES's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 18,229,790 to 14,685,148, a change of -3,544,642 (-19.4%).
- Net loss of 3,544,642 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.54 Million | -24.14% |
| Total Change | €- | -19.44% |
Book Value vs Market Value Analysis
This analysis compares ARROWSTAR RESOURCES's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €0.23 | €0.20 | x |
| 2021-12-31 | €0.34 | €0.20 | x |
| 2022-12-31 | €0.33 | €0.20 | x |
| 2023-12-31 | €0.26 | €0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ARROWSTAR RESOURCES utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.95%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.20x
- Recent ROE (-24.14%) is above the historical average (-33.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -75.51% | -304.71% | 0.18x | 1.36x | €-8.62 Million |
| 2021 | -12.29% | -48.86% | 0.20x | 1.29x | €-4.99 Million |
| 2022 | -23.49% | -32.20% | 0.42x | 1.74x | €-6.10 Million |
| 2023 | -24.14% | -15.95% | 0.69x | 2.20x | €-5.01 Million |
Industry Comparison
This section compares ARROWSTAR RESOURCES's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ARROWSTAR RESOURCES (D2E) | €13.37 Million | -75.51% | 1.30x | $132.14K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |